Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

KalVista Posts 154% Expense Jump in Q1

TheMotleyFool 
0 0 11.09.25
KalVista Posts 154% Expense Jump in Q1
 

KalVista Pharmaceuticals (NASDAQ:KALV), a biopharmaceutical company developing and commercializing therapies for rare diseases, announced its earnings for the first quarter of fiscal 2026 on Sept. 11, 2025. The major headline was the commercial launch of EKTERLY (sebetralstat), the first and only oral treatment for acute hereditary angioedema (HAE) attacks, which received both U.S. Food and Drug Administration (FDA) and United Kingdom regulatory approval during the quarter.

While early patient uptake exceeded management expectations, this achievement was accompanied by a significant surge in commercialization costs, highlighting both the scale of the market opportunity and the operational and financial challenges ahead. The quarter marked a major transition for the company as it moves from research focus to commercial operations.

Source: KalVista Pharmaceuticals. Note: Fiscal 2026's first quarter ended July 31, 2025. Fiscal 2025's Q1 ended July 31, 2024.

Continue reading


Source Fool.com

Carbylan Therapeutics Inc Stock

€9.50
-6.860%
Carbylan Therapeutics Inc took a tumble today and lost -€0.700 (-6.860%).

Show more
Like: 0
KALV
Share

Comments

Not a member yet? Sign up for free!